Dublin-based Jazz Pharmaceuticals plc's buyout of Cavion Inc. via merger with a subsidiary had some on Wall Street scratching their chins, as the takeover undoubtedly adds to the central nervous system (CNS) pipeline but with lingering development risks. Read More
The multiple months that typically separate a successful round of fundraising and entering the clinic are being brushed aside by Landos Biopharma Inc. as the company races toward two phase II trials following its just completed $60 million series B financing. Read More
While many companies use viruses and viral vectors to deliver gene therapy and to modify cells for CAR T treatments, others have shunned adeno-associated viruses (AAV) and lentiviral vectors for other methods to deliver DNA and RNA into the cells. Read More
Plasma coagulation factor VII (FVII), FIX and FX have been shown to be effective antibacterial proteins against drug-resistant gram-negative bacteria and may offer alternative strategies for combating the increasingly urgent global health threat posed by those resistant pathogens. Read More
Researchers at Carnegie Mellon University (CMU) in Pittsburgh have solved a critical problem in 3D bioprinting of tissue scaffolding. The technique is an advanced version of Freeform Reversible Embedding of Suspended Hydrogels (FRESH) that enables 3D printing with collagen to create biological components of unprecedented complexity and detail. A paper detailing use of the technique to create components of the human heart appeared in Science. Read More
Luca Biologics, of Baltimore, published research in mBio showing that certain types of Lactobacillus within the vagina can make it easier or harder for sexually transmitted diseases, especially chlamydia, to be transmitted. Read More
Looking to improve the integrity of the U.S. drug supply chain and patient safety, the FDA Tuesday put drug companies on notice that it will inactivate listing records that are outdated or inaccurate as of Sept. 12. Drugs with inactivated listings cannot be legally marketed in the U.S. Read More
Kromatid Inc., of Denver, said it completed a series A financing round with Denver-based First Capital Ventures, with the amount cited in an SEC filing as $1.85 million. The company said the funding will support development of its directional genomic hybridization, or DGH, platform to provide the gene editing field with tools for single cell structural genomic analysis to support therapeutic development programs. Read More
We're working to enhance BioWorld's news services by moving to a brand-new platform later this year. Upgrades will include: same-day news delivery, improved functionality, easier accessibility on all devices, more analysis and dynamic data visualization. We value your opinion on these changes. Please take 2 minutes to complete this short survey to help guide our work: https://www.surveymonkey.com/r/Q5TK8JL Read More
Shares of Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH) spiked Tuesday, rising 80% to $35.90 as results of a pivotal phase III study showed its lead candidate, ripretinib, enabled people with fourth-line and beyond gastrointestinal stromal tumors (GIST) to live a median of 6.3 months before disease progression vs. one month with a placebo. Ripretinib also reduced the risk of disease progression or death by 85%. Read More
